ArticleThoracic cancer2023

Predicting pathological response to neoadjuvant or conversion chemoimmunotherapy in stage IB-III non-small cell lung cancer patients using radiomic features.

Nong Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.